High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
The use of high-sensitivity C-reactive protein (hsCRP) for risk stratification for cardiovascular disease is supported by epidemiologic evidence but remains controversial. The metabolic milieu in which hsCRP is likely to be elevated, namely abdominal obesity and insulin resistance, provides a framework for the understanding of the role of hsCRP as well its limitations. This commentary provides a critical assessment of the data in support of the use of hsCRP in clinical practice.
Ben-Yehuda
Ori
O
Department of Medicine, University of California, San Diego Medical Center, San Diego, California 92103, USA. obyehuda@acc.org
D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000097:blood; D018570:Risk Assessment
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D002784:Cholesterol